;PMID: 3492267
;source_file_1951.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..140] = [t:41..140]
;2)section:[e:144..181] = [t:144..181]
;3)sentence:[e:185..433] = [t:185..433]
;4)sentence:[e:434..585] = [t:434..585]
;5)sentence:[e:586..756] = [t:586..756]
;6)sentence:[e:757..981] = [t:757..981]
;7)sentence:[e:982..1092] = [t:982..1092]
;8)sentence:[e:1093..1256] = [t:1093..1256]
;9)sentence:[e:1258..1576] = [t:1258..1576]
;10)sentence:[e:1577..1832] = [t:1577..1832]
;11)sentence:[e:1833..1929] = [t:1833..1929]
;12)sentence:[e:1930..2260] = [t:1930..2260]
;13)sentence:[e:2262..2547] = [t:2262..2547]
;14)section:[e:2551..2595] = [t:2551..2595]

;section 0 Span:0..35
;Cancer Res. 1987 Feb 1;47(3):760-6.
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..10] Res) (.:[10..11] .) (CD:[12..16] 1987)
        (NNP:[17..20] Feb) (CD:[21..26] 1;47-LRB-) (CD:[26..27] 3)
        (-RRB-:[27..28] -RRB-) (CD:[28..32] :760) (HYPH:[32..33] -)
        (CD:[33..35] 6.)))

;sentence 1 Span:41..140
;Inhibition of epidermal xenobiotic metabolism in SENCAR mice by naturally 
;occurring plant phenols.
;[65..75]:substance:"xenobiotic"
;[132..139]:substance:"phenols"
(SENT
  (NP-HLN
    (NP (NN:[41..51] Inhibition))
    (PP (IN:[52..54] of)
      (NP (JJ:[55..64] epidermal) (JJ:[65..75] xenobiotic)
          (NN:[76..86] metabolism)))
    (PP-LOC (IN:[87..89] in)
      (NP (NN:[90..96] SENCAR) (NNS:[97..101] mice)))
    (PP (IN:[102..104] by)
      (NP
        (ADJP (RB:[105..114] naturally) (VBG:[116..125] occurring))
        (NN:[126..131] plant) (NNS:[132..139] phenols)))
    (.:[139..140] .)))

;section 2 Span:144..181
;Das M, Mukhtar H, Bik DP, Bickers DR.
(SEC
  (FRAG (NNP:[144..147] Das) (NNP:[148..150] M,) (NNP:[151..158] Mukhtar)
        (NNP:[159..160] H) (,:[160..161] ,) (NNP:[162..165] Bik)
        (NNP:[166..168] DP) (,:[168..169] ,) (NNP:[170..177] Bickers)
        (NNP:[178..181] DR.)))

;sentence 3 Span:185..433
;Naturally occurring plant phenols such as tannic acid, quercetin, myricetin,
;and  anthraflavic acid have been shown to inhibit the mutagenicity of several
; bay-region diol-epoxides of polycyclic aromatic hydrocarbons including 
;benzo(a)pyrene (BP).
;[211..218]:substance:"phenols"
;[227..238]:substance:"tannic acid"
;[240..249]:substance:"quercetin"
;[251..260]:substance:"myricetin"
;[267..284]:substance:"anthraflavic acid"
;[352..365]:substance:"diol-epoxides"
;[369..401]:substance:"polycyclic aromatic hydrocarbons"
;[413..427]:substance:"benzo(a)pyrene"
;[429..431]:substance:"BP"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (ADJP (RB:[185..194] Naturally) (VBG:[195..204] occurring))
        (NN:[205..210] plant) (NNS:[211..218] phenols))
      (PP (JJ:[219..223] such) (IN:[224..226] as)
        (NP
          (NP (JJ:[227..233] tannic) (NN:[234..238] acid))
          (,:[238..239] ,)
          (NP (NN:[240..249] quercetin))
          (,:[249..250] ,)
          (NP (NN:[251..260] myricetin))
          (,:[260..261] ,) (CC:[262..265] and)
          (NP (JJ:[267..279] anthraflavic) (NN:[280..284] acid)))))
    (VP (VBP:[285..289] have)
      (VP (VBN:[290..294] been)
        (VP (VBN:[295..300] shown)
          (S
            (NP-SBJ-1 (-NONE-:[300..300] *))
            (VP (TO:[301..303] to)
              (VP (VB:[304..311] inhibit)
                (NP
                  (NP (DT:[312..315] the) (NN:[316..328] mutagenicity))
                  (PP (IN:[329..331] of)
                    (NP
                      (NP (JJ:[332..339] several)
                        (NML (NN:[341..344] bay) (HYPH:[344..345] -)
                             (NN:[345..351] region))
                         (NN:[352..356] diol) (HYPH:[356..357] -)
                         (NNS:[357..365] epoxides))
                      (PP (IN:[366..368] of)
                        (NP (JJ:[369..379] polycyclic) (JJ:[380..388] aromatic)
                            (NNS:[389..401] hydrocarbons)))
                      (PP (VBG:[402..411] including)
                        (NP
                          (NP (NN:[413..427] benzo-LRB-a-RRB-pyrene))
                          (NP (-LRB-:[428..429] -LRB-) (NN:[429..431] BP)
                              (-RRB-:[431..432] -RRB-)))))))))))))
    (.:[432..433] .)))

;sentence 4 Span:434..585
;The present study was designed to determine whether these  plant phenols can
;alter epidermal cytochrome P-450-dependent monooxygenases in  SENCAR mice.
;[499..506]:substance:"phenols"
;[527..568]:substance:"cytochrome P-450-dependent monooxygenases"
(SENT
  (S
    (NP-SBJ-1 (DT:[434..437] The) (JJ:[438..445] present) (NN:[446..451] study))
    (VP (VBD:[452..455] was)
      (VP (VBN:[456..464] designed)
        (NP-1 (-NONE-:[464..464] *))
        (S-PRP
          (NP-SBJ (-NONE-:[464..464] *))
          (VP (TO:[465..467] to)
            (VP (VB:[468..477] determine)
              (SBAR (IN:[478..485] whether)
                (S
                  (NP-SBJ (DT:[486..491] these) (NN:[493..498] plant)
                          (NNS:[499..506] phenols))
                  (VP (MD:[507..510] can)
                    (VP (VB:[511..516] alter)
                      (NP (JJ:[517..526] epidermal)
                        
                        (ADJP
                          (NML (NN:[527..537] cytochrome) (NN:[538..543] P-450))
                          (HYPH:[543..544] -) (JJ:[544..553] dependent))
                        (NNS:[554..568] monooxygenases))
                      (PP-LOC (IN:[569..571] in)
                        (NP (NN:[573..579] SENCAR) (NNS:[580..584] mice))))))))))))
    (.:[584..585] .)))

;sentence 5 Span:586..756
;In vitro addition of these plant phenols to epidermal microsomal 
;preparations inhibited aryl hydrocarbon hydroxylase (AHH) activity in a 
;concentration-dependent manner.
;[619..626]:substance:"phenols"
;[675..703]:cyp450:"aryl hydrocarbon hydroxylase"
;[705..708]:cyp450:"AHH"
(SENT
  (S
    (NP-SBJ
      (NP
        (ADJP (FW:[586..588] In) (FW:[589..594] vitro))
        (NN:[595..603] addition))
      (PP (IN:[604..606] of)
        (NP (DT:[607..612] these) (NN:[613..618] plant) (NNS:[619..626] phenols)))
      (PP (TO:[627..629] to)
        (NP (JJ:[630..639] epidermal) (JJ:[640..650] microsomal)
            (NNS:[652..664] preparations))))
    (VP (VBD:[665..674] inhibited)
      (NP
        (NML
          (NML (NN:[675..679] aryl) (NN:[680..691] hydrocarbon)
               (NN:[692..703] hydroxylase))
          (NML (-LRB-:[704..705] -LRB-) (NN:[705..708] AHH)
               (-RRB-:[708..709] -RRB-)))
        (NN:[710..718] activity))
      (PP (IN:[719..721] in)
        (NP (DT:[722..723] a)
          (ADJP (NN:[725..738] concentration) (HYPH:[738..739] -)
                (JJ:[739..748] dependent))
          (NN:[749..755] manner))))
    (.:[755..756] .)))

;sentence 6 Span:757..981
;The 50% inhibitory concentrations for tannic  acid, myricetin, quercetin, and
;anthraflavic acid ranged from 4.4 X 10(-5) M to  12.4 X 10(-5) M in
;microsomes prepared from control and  3-methylcholanthrene-pretreated
;animals.
;[761..764]:quantitative-value:"50%"
;[765..790]:quantitative-name:"inhibitory concentrations"
;[795..807]:substance:"tannic  acid"
;[809..818]:substance:"myricetin"
;[820..829]:substance:"quercetin"
;[835..852]:substance:"anthraflavic acid"
;[865..877]:quantitative-value:"4.4 X 10(-5)"
;[878..879]:quantitative-units:"M"
;[884..897]:quantitative-value:"12.4 X 10(-5)"
;[898..899]:quantitative-units:"M"
;[941..961]:substance:"3-methylcholanthrene"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[757..760] The)
        (NML (CD:[761..763] 50) (NN:[763..764] %))
         (JJ:[765..775] inhibitory) (NNS:[776..790] concentrations))
      (PP (IN:[791..794] for)
        (NP
          (NP (JJ:[795..801] tannic) (NN:[803..807] acid))
          (,:[807..808] ,)
          (NP (NN:[809..818] myricetin))
          (,:[818..819] ,)
          (NP (NN:[820..829] quercetin))
          (,:[829..830] ,) (CC:[831..834] and)
          (NP (JJ:[835..847] anthraflavic) (NN:[848..852] acid)))))
    (VP (VBD:[853..859] ranged)
      (PP
        (PP (IN:[860..864] from)
          (NP
            (QP (CD:[865..868] 4.4) (SYM:[869..870] X)
                (CD:[871..877] 10-LRB--5-RRB-))
            (NN:[878..879] M)))
        (PP (TO:[880..882] to)
          (NP
            (QP (CD:[884..888] 12.4) (SYM:[889..890] X)
                (CD:[891..897] 10-LRB--5-RRB-))
            (NN:[898..899] M))))
      (PP-LOC (IN:[900..902] in)
        (NP
          (NP (NNS:[903..913] microsomes))
          (VP (VBN:[914..922] prepared)
            (NP (-NONE-:[922..922] *))
            (PP (IN:[923..927] from)
              (NP
                (NP (NN:[928..935] control)
                  (NML-1 (-NONE-:[935..935] *P*)))
                (CC:[936..939] and)
                (NP
                  (ADJP (NN:[941..961] 3-methylcholanthrene) (HYPH:[961..962] -)
                        (VBN:[962..972] pretreated))
                  (NML-1 (NNS:[973..980] animals)))))))))
    (.:[980..981] .)))

;sentence 7 Span:982..1092
;Of the plant phenols studied tannic  acid was found to be the most potent
;inhibitor of epidermal AHH activity.
;[995..1002]:substance:"phenols"
;[1011..1023]:substance:"tannic  acid"
;[1056..1065]:substance:"inhibitor"
;[1079..1082]:cyp450:"AHH"
(SENT
  (S
    (PP (IN:[982..984] Of)
      (NP
        (NP (DT:[985..988] the) (NN:[989..994] plant) (NNS:[995..1002] phenols))
        (VP (VBN:[1003..1010] studied)
          (NP (-NONE-:[1010..1010] *)))))
    (NP-SBJ-1 (JJ:[1011..1017] tannic) (NN:[1019..1023] acid))
    (VP (VBD:[1024..1027] was)
      (VP (VBN:[1028..1033] found)
        (S
          (NP-SBJ-1 (-NONE-:[1033..1033] *))
          (VP (TO:[1034..1036] to)
            (VP (VB:[1037..1039] be)
              (NP-PRD
                (NP (DT:[1040..1043] the)
                  (ADJP (RBS:[1044..1048] most) (JJ:[1049..1055] potent))
                  (NN:[1056..1065] inhibitor))
                (PP (IN:[1066..1068] of)
                  (NP (JJ:[1069..1078] epidermal) (NN:[1079..1082] AHH)
                      (NN:[1083..1091] activity)))))))))
    (.:[1091..1092] .)))

;sentence 8 Span:1093..1256
;Tannic  acid, quercetin, myricetin, and anthraflavic acid exhibited a mixed
;type of  inhibitory effect with Ki values of 81, 63, 135, and 165 microM,
;respectively.
;[1093..1105]:substance:"Tannic  acid"
;[1107..1116]:substance:"quercetin"
;[1118..1127]:substance:"myricetin"
;[1133..1150]:substance:"anthraflavic acid"
;[1201..1203]:quantitative-name:"Ki"
;[1214..1216]:quantitative-value:"81"
;[1218..1220]:quantitative-value:"63"
;[1222..1225]:quantitative-value:"135"
;[1231..1234]:quantitative-value:"165"
;[1235..1241]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1093..1099] Tannic) (NN:[1101..1105] acid))
      (,:[1105..1106] ,)
      (NP (NN:[1107..1116] quercetin))
      (,:[1116..1117] ,)
      (NP (NN:[1118..1127] myricetin))
      (,:[1127..1128] ,) (CC:[1129..1132] and)
      (NP (JJ:[1133..1145] anthraflavic) (NN:[1146..1150] acid)))
    (VP (VBD:[1151..1160] exhibited)
      (NP
        (NP (DT:[1161..1162] a) (VBN:[1163..1168] mixed) (NN:[1169..1173] type))
        (PP (IN:[1174..1176] of)
          (NP (JJ:[1178..1188] inhibitory) (NN:[1189..1195] effect))))
      (PP (IN:[1196..1200] with)
        (NP
          (NP (NN:[1201..1203] Ki) (NNS:[1204..1210] values))
          (PP (IN:[1211..1213] of)
            (NP
              (NP (CD:[1214..1216] 81)
                (NML-1 (-NONE-:[1216..1216] *P*)))
              (,:[1216..1217] ,)
              (NP (CD:[1218..1220] 63)
                (NML-1 (-NONE-:[1220..1220] *P*)))
              (,:[1220..1221] ,)
              (NP (CD:[1222..1225] 135)
                (NML-1 (-NONE-:[1225..1225] *P*)))
              (,:[1225..1226] ,) (CC:[1227..1230] and)
              (NP (CD:[1231..1234] 165)
                (NML-1 (NN:[1235..1241] microM)))))))
      (,:[1241..1242] ,)
      (ADVP (RB:[1243..1255] respectively)))
    (.:[1255..1256] .)))

;sentence 9 Span:1258..1576
;In vitro addition of these plant phenols (240 microM) to the incubation
;mixture  prepared from control and 3-methylcholanthrene-treated animals
;resulted in  varying degrees of inhibition of epidermal microsomal AHH
;(57-92%),  ethoxycoumarin O-deethylase (19-58%), and ethoxyresorufin
;O-deethylase (33-85%)  activities.
;[1291..1298]:substance:"phenols"
;[1300..1303]:quantitative-value:"240"
;[1304..1310]:quantitative-units:"microM"
;[1365..1385]:substance:"3-methylcholanthrene"
;[1469..1472]:cyp450:"AHH"
;[1474..1480]:quantitative-value:"57-92%"
;[1484..1511]:substance:"ethoxycoumarin O-deethylase"
;[1513..1519]:quantitative-value:"19-58%"
;[1526..1554]:cyp450:"ethoxyresorufin O-deethylase"
;[1556..1562]:quantitative-value:"33-85%"
(SENT
  (S
    (NP-SBJ
      (NP
        (ADJP (FW:[1258..1260] In) (FW:[1261..1266] vitro))
        (NN:[1267..1275] addition))
      (PP (IN:[1276..1278] of)
        (NP (DT:[1279..1284] these) (NN:[1285..1290] plant)
            (NNS:[1291..1298] phenols)
          (PRN (-LRB-:[1299..1300] -LRB-)
            (NP (CD:[1300..1303] 240) (NN:[1304..1310] microM))
            (-RRB-:[1310..1311] -RRB-))))
      (PP (TO:[1312..1314] to)
        (NP
          (NP (DT:[1315..1318] the) (NN:[1319..1329] incubation)
              (NN:[1330..1337] mixture))
          (VP (VBN:[1339..1347] prepared)
            (NP (-NONE-:[1347..1347] *))
            (PP (IN:[1348..1352] from)
              (NP
                (NP (NN:[1353..1360] control)
                  (NML-3 (-NONE-:[1360..1360] *P*)))
                (CC:[1361..1364] and)
                (NP
                  (ADJP (NN:[1365..1385] 3-methylcholanthrene)
                        (HYPH:[1385..1386] -) (VBN:[1386..1393] treated))
                  (NML-3 (NNS:[1394..1401] animals)))))))))
    (VP (VBD:[1402..1410] resulted)
      (PP-CLR (IN:[1411..1413] in)
        (NP
          (NP (VBG:[1415..1422] varying) (NNS:[1423..1430] degrees))
          (PP (IN:[1431..1433] of)
            (NP
              (NP (NN:[1434..1444] inhibition))
              (PP (IN:[1445..1447] of)
                (NP
                  (NP
                    (ADJP-2 (JJ:[1448..1457] epidermal)
                            (JJ:[1458..1468] microsomal))
                    (NN:[1469..1472] AHH)
                    (PRN (-LRB-:[1473..1474] -LRB-)
                      (NP
                        (QP (CD:[1474..1476] 57) (HYPH:[1476..1477] -)
                            (CD:[1477..1479] 92))
                        (NN:[1479..1480] %))
                      (-RRB-:[1480..1481] -RRB-))
                    (NML-1 (-NONE-:[1481..1481] *P*)))
                  (,:[1481..1482] ,)
                  (NP
                    (ADJP-2 (-NONE-:[1482..1482] *P*))
                    (NML (NN:[1484..1498] ethoxycoumarin)
                         (NN:[1499..1511] O-deethylase))
                    (PRN (-LRB-:[1512..1513] -LRB-)
                      (NP
                        (QP (CD:[1513..1515] 19) (HYPH:[1515..1516] -)
                            (CD:[1516..1518] 58))
                        (NN:[1518..1519] %))
                      (-RRB-:[1519..1520] -RRB-))
                    (NML-1 (-NONE-:[1520..1520] *P*)))
                  (,:[1520..1521] ,) (CC:[1522..1525] and)
                  (NP
                    (ADJP-2 (-NONE-:[1525..1525] *P*))
                    (NML (NN:[1526..1541] ethoxyresorufin)
                         (NN:[1542..1554] O-deethylase))
                    (PRN (-LRB-:[1555..1556] -LRB-)
                      (NP
                        (QP (CD:[1556..1558] 33) (HYPH:[1558..1559] -)
                            (CD:[1559..1561] 85))
                        (NN:[1561..1562] %))
                      (-RRB-:[1562..1563] -RRB-))
                    (NML-1 (NNS:[1565..1575] activities))))))))))
    (.:[1575..1576] .)))

;sentence 10 Span:1577..1832
;High pressure liquid chromatographic analysis of the organic  solvent-soluble
;metabolites of BP produced by epidermal microsomes indicated a  substantial
;decrease in the formation of BP-diols (23-67%) and BP-phenols  (29-57%) by
;each of the plant phenols.
;[1630..1646]:substance:"organic  solvent"
;[1647..1666]:substance:"soluble metabolites"
;[1670..1672]:substance:"BP"
;[1760..1768]:substance:"BP-diols"
;[1770..1776]:quantitative-value:"23-67%"
;[1782..1792]:substance:"BP-phenols"
;[1795..1801]:quantitative-value:"29-57%"
;[1824..1831]:substance:"phenols"
(SENT
  (S
    (NP-SBJ
      (NP
        (ADJP (JJ:[1577..1581] High) (NN:[1582..1590] pressure))
        (JJ:[1591..1597] liquid) (JJ:[1598..1613] chromatographic)
         (NN:[1614..1622] analysis))
      (PP (IN:[1623..1625] of)
        (NP
          (NP
            (NP (DT:[1626..1629] the)
              (ADJP
                (NML (JJ:[1630..1637] organic) (NN:[1639..1646] solvent))
                (HYPH:[1646..1647] -) (JJ:[1647..1654] soluble))
              (NNS:[1655..1666] metabolites))
            (PP (IN:[1667..1669] of)
              (NP (NN:[1670..1672] BP))))
          (VP (VBN:[1673..1681] produced)
            (NP (-NONE-:[1681..1681] *))
            (PP (IN:[1682..1684] by)
              (NP-LGS (JJ:[1685..1694] epidermal) (NNS:[1695..1705] microsomes)))))))
    (VP (VBD:[1706..1715] indicated)
      (NP
        (NP (DT:[1716..1717] a) (JJ:[1719..1730] substantial)
            (NN:[1731..1739] decrease))
        (PP (IN:[1740..1742] in)
          (NP
            (NP (DT:[1743..1746] the) (NN:[1747..1756] formation))
            (PP (IN:[1757..1759] of)
              (NP
                (NP
                   (NN:[1760..1762] BP) (HYPH:[1762..1763] -)
                   (NNS:[1763..1768] diols)
                  (PRN (-LRB-:[1769..1770] -LRB-)
                    (NP
                      (QP (CD:[1770..1772] 23) (HYPH:[1772..1773] -)
                          (CD:[1773..1775] 67))
                      (NN:[1775..1776] %))
                    (-RRB-:[1776..1777] -RRB-)))
                (CC:[1778..1781] and)
                (NP
                   (NN:[1782..1784] BP) (HYPH:[1784..1785] -)
                   (NNS:[1785..1792] phenols)
                  (PRN (-LRB-:[1794..1795] -LRB-)
                    (NP
                      (QP (CD:[1795..1797] 29) (HYPH:[1797..1798] -)
                          (CD:[1798..1800] 57))
                      (NN:[1800..1801] %))
                    (-RRB-:[1801..1802] -RRB-)))))
            (PP (IN:[1803..1805] by)
              (NP
                (NP (DT:[1806..1810] each))
                (PP (IN:[1811..1813] of)
                  (NP (DT:[1814..1817] the) (NN:[1818..1823] plant)
                      (NNS:[1824..1831] phenols)))))))))
    (.:[1831..1832] .)))

;sentence 11 Span:1833..1929
;The formation of BP-7,8-diol was  substantially inhibited (29-52%) by each of
;the plant phenols.
;[1850..1861]:substance:"BP-7,8-diol"
;[1892..1898]:quantitative-value:"29-52%"
;[1921..1928]:substance:"phenols"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1833..1836] The) (NN:[1837..1846] formation))
      (PP (IN:[1847..1849] of)
        (NP (NN:[1850..1852] BP) (HYPH:[1852..1853] -)
            (NN:[1853..1861] 7,8-diol))))
    (VP (VBD:[1862..1865] was)
      (ADVP (RB:[1867..1880] substantially))
      (VP (VBN:[1881..1890] inhibited)
        (NP-1 (-NONE-:[1890..1890] *))
        (PRN (-LRB-:[1891..1892] -LRB-)
          (NP
            (QP (CD:[1892..1894] 29) (HYPH:[1894..1895] -) (CD:[1895..1897] 52))
            (NN:[1897..1898] %))
          (-RRB-:[1898..1899] -RRB-))
        (PP (IN:[1900..1902] by)
          (NP-LGS
            (NP (DT:[1903..1907] each))
            (PP (IN:[1908..1910] of)
              (NP (DT:[1911..1914] the) (NN:[1915..1920] plant)
                  (NNS:[1921..1928] phenols)))))))
    (.:[1928..1929] .)))

;sentence 12 Span:1930..2260
;Further in vivo  studies showed that a single topical application of tannic
;acid, quercetin, and  myricetin greatly diminished epidermal AHH (53-65%),
;ethoxycoumarin O-deethylase  (30-68%), and ethoxyresorufin O-deethylase
;(66-97%) activities whereas  anthraflavic acid was ineffective in this regard
;even when repeatedly applied.
;[1999..2010]:substance:"tannic acid"
;[2012..2021]:substance:"quercetin"
;[2028..2037]:substance:"myricetin"
;[2067..2070]:cyp450:"AHH"
;[2072..2078]:quantitative-value:"53-65%"
;[2081..2108]:substance:"ethoxycoumarin O-deethylase"
;[2111..2117]:quantitative-value:"30-68%"
;[2124..2152]:cyp450:"ethoxyresorufin O-deethylase"
;[2154..2160]:quantitative-value:"66-97%"
;[2182..2199]:substance:"anthraflavic acid"
(SENT
  (S
    (NP-SBJ (JJ:[1930..1937] Further)
      (ADJP (FW:[1938..1940] in) (FW:[1941..1945] vivo))
      (NNS:[1947..1954] studies))
    (VP (VBD:[1955..1961] showed)
      (SBAR (IN:[1962..1966] that)
        (S
          (NP-SBJ
            (NP (DT:[1967..1968] a) (JJ:[1969..1975] single)
                (JJ:[1976..1983] topical) (NN:[1984..1995] application))
            (PP (IN:[1996..1998] of)
              (NP
                (NP (JJ:[1999..2005] tannic) (NN:[2006..2010] acid))
                (,:[2010..2011] ,)
                (NP (NN:[2012..2021] quercetin))
                (,:[2021..2022] ,) (CC:[2023..2026] and)
                (NP (NN:[2028..2037] myricetin)))))
          (ADVP (RB:[2038..2045] greatly))
          (VP (VBD:[2046..2056] diminished)
            (NP
              (NP
                (ADJP-4 (JJ:[2057..2066] epidermal))
                (NN:[2067..2070] AHH)
                (PRN (-LRB-:[2071..2072] -LRB-)
                  (NP
                    (QP (CD:[2072..2074] 53) (HYPH:[2074..2075] -)
                        (CD:[2075..2077] 65))
                    (NN:[2077..2078] %))
                  (-RRB-:[2078..2079] -RRB-))
                (NML-3 (-NONE-:[2079..2079] *P*)))
              (,:[2079..2080] ,)
              (NP
                (ADJP-4 (-NONE-:[2080..2080] *P*))
                (NML (NN:[2081..2095] ethoxycoumarin)
                     (NN:[2096..2108] O-deethylase))
                (PRN (-LRB-:[2110..2111] -LRB-)
                  (NP
                    (QP (CD:[2111..2113] 30) (HYPH:[2113..2114] -)
                        (CD:[2114..2116] 68))
                    (NN:[2116..2117] %))
                  (-RRB-:[2117..2118] -RRB-))
                (NML-3 (-NONE-:[2118..2118] *P*)))
              (,:[2118..2119] ,) (CC:[2120..2123] and)
              (NP
                (ADJP-4 (-NONE-:[2123..2123] *P*))
                (NML (NN:[2124..2139] ethoxyresorufin)
                     (NN:[2140..2152] O-deethylase))
                (PRN (-LRB-:[2153..2154] -LRB-)
                  (NP
                    (QP (CD:[2154..2156] 66) (HYPH:[2156..2157] -)
                        (CD:[2157..2159] 97))
                    (NN:[2159..2160] %))
                  (-RRB-:[2160..2161] -RRB-))
                (NML-3 (NNS:[2162..2172] activities))))
            (SBAR-ADV (IN:[2173..2180] whereas)
              (S
                (NP-SBJ (JJ:[2182..2194] anthraflavic) (NN:[2195..2199] acid))
                (VP (VBD:[2200..2203] was)
                  (ADJP-PRD (JJ:[2204..2215] ineffective))
                  (PP (IN:[2216..2218] in)
                    (NP (DT:[2219..2223] this) (NN:[2224..2230] regard)))
                  (SBAR
                    (ADVP (RB:[2231..2235] even))
                    (WHADVP-2 (WRB:[2236..2240] when))
                    (S
                      (NP-SBJ-1 (-NONE-:[2240..2240] *))
                      (ADVP (RB:[2241..2251] repeatedly))
                      (VP (VBN:[2252..2259] applied)
                        (NP-1 (-NONE-:[2259..2259] *))
                        (ADVP-TMP-2 (-NONE-:[2259..2259] *T*))))))))))))
    (.:[2259..2260] .)))

;sentence 13 Span:2262..2547
;Our results indicate that plant phenols have substantial though variable 
;inhibitory effects on epidermal monooxygenase activities and BP metabolism 
;suggesting that these compounds may be capable of inhibiting the carcinogenic
; effects of polycyclic aromatic hydrocarbons in the skin.
;[2294..2301]:substance:"phenols"
;[2368..2381]:substance:"monooxygenase"
;[2397..2399]:substance:"BP"
;[2434..2443]:substance:"compounds"
;[2502..2534]:substance:"polycyclic aromatic hydrocarbons"
(SENT
  (S
    (NP-SBJ (PRP$:[2262..2265] Our) (NNS:[2266..2273] results))
    (VP (VBP:[2274..2282] indicate)
      (SBAR (IN:[2283..2287] that)
        (S
          (NP-SBJ (NN:[2288..2293] plant) (NNS:[2294..2301] phenols))
          (VP (VBP:[2302..2306] have)
            (NP
              (NP
                (ADJP (JJ:[2307..2318] substantial)
                  (PP (IN:[2319..2325] though)
                    (ADJP (JJ:[2326..2334] variable))))
                (JJ:[2336..2346] inhibitory) (NNS:[2347..2354] effects))
              (PP (IN:[2355..2357] on)
                (NP
                  (NP (JJ:[2358..2367] epidermal)
                      (NN:[2368..2381] monooxygenase)
                      (NNS:[2382..2392] activities))
                  (CC:[2393..2396] and)
                  (NP (NN:[2397..2399] BP) (NN:[2400..2410] metabolism)))))
            (S-ADV
              (NP-SBJ (-NONE-:[2410..2410] *))
              (VP (VBG:[2412..2422] suggesting)
                (SBAR (IN:[2423..2427] that)
                  (S
                    (NP-SBJ (DT:[2428..2433] these) (NNS:[2434..2443] compounds))
                    (VP (MD:[2444..2447] may)
                      (VP (VB:[2448..2450] be)
                        (ADJP-PRD (JJ:[2451..2458] capable)
                          (PP (IN:[2459..2461] of)
                            (S-NOM
                              (NP-SBJ (-NONE-:[2461..2461] *))
                              (VP (VBG:[2462..2472] inhibiting)
                                (NP
                                  (NP (DT:[2473..2476] the)
                                      (JJ:[2477..2489] carcinogenic)
                                      (NNS:[2491..2498] effects))
                                  (PP (IN:[2499..2501] of)
                                    (NP (JJ:[2502..2512] polycyclic)
                                        (JJ:[2513..2521] aromatic)
                                        (NNS:[2522..2534] hydrocarbons))))
                                (PP-LOC (IN:[2535..2537] in)
                                  (NP (DT:[2538..2541] the)
                                      (NN:[2542..2546] skin)))))))))))))))))
    (.:[2546..2547] .)))

;section 14 Span:2551..2595
;PMID: 3492267 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2551..2555] PMID) (::[2555..2556] :) (CD:[2557..2564] 3492267)
        (NN:[2565..2566] -LSB-) (NNP:[2566..2572] PubMed) (::[2573..2574] -)
        (NN:[2575..2582] indexed) (IN:[2583..2586] for)
        (NNP:[2587..2595] MEDLINE-RSB-)))
